64 false false false false false false false false false false true false false false false true false No description of principal activity 2024-10-01 Sage Accounts Production Advanced 2025 - FRS102_2025 231,237 231,237 12,080 12,080 219,157 xbrli:pure xbrli:shares iso4217:GBP 05937877 2024-10-01 2025-09-30 05937877 2025-09-30 05937877 2024-09-30 05937877 2023-10-01 2024-09-30 05937877 2024-09-30 05937877 2023-09-30 05937877 core:FurnitureFittings 2024-10-01 2025-09-30 05937877 bus:Director5 2024-10-01 2025-09-30 05937877 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-09-30 05937877 core:FurnitureFittings 2024-09-30 05937877 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-10-01 2025-09-30 05937877 core:WithinOneYear 2025-09-30 05937877 core:WithinOneYear 2024-09-30 05937877 core:AfterOneYear 2025-09-30 05937877 core:AfterOneYear 2024-09-30 05937877 core:ShareCapital 2025-09-30 05937877 core:ShareCapital 2024-09-30 05937877 core:SharePremium 2025-09-30 05937877 core:SharePremium 2024-09-30 05937877 core:RetainedEarningsAccumulatedLosses 2025-09-30 05937877 core:RetainedEarningsAccumulatedLosses 2024-09-30 05937877 core:AcceleratedTaxDepreciationDeferredTax 2025-09-30 05937877 core:AcceleratedTaxDepreciationDeferredTax 2024-09-30 05937877 core:TaxLossesCarry-forwardsDeferredTax 2025-09-30 05937877 core:TaxLossesCarry-forwardsDeferredTax 2024-09-30 05937877 bus:Director1 2024-10-01 2025-09-30 05937877 bus:SmallEntities 2024-10-01 2025-09-30 05937877 bus:AuditExempt-NoAccountantsReport 2024-10-01 2025-09-30 05937877 bus:SmallCompaniesRegimeForAccounts 2024-10-01 2025-09-30 05937877 bus:PrivateLimitedCompanyLtd 2024-10-01 2025-09-30 05937877 bus:FullAccounts 2024-10-01 2025-09-30 05937877 core:ComputerEquipment 2024-09-30 05937877 core:PlantMachinery 2024-09-30 05937877 core:ComputerEquipment 2024-10-01 2025-09-30 05937877 core:PlantMachinery 2024-10-01 2025-09-30 05937877 core:ComputerEquipment 2025-09-30 05937877 core:PlantMachinery 2025-09-30
COMPANY REGISTRATION NUMBER: 05937877
Diagnostic World Limited
Filleted Unaudited Financial Statements
30 September 2025
Diagnostic World Limited
Financial Statements
Year ended 30 September 2025
Contents
Page
Statement of financial position
1
Notes to the financial statements
3
Diagnostic World Limited
Statement of Financial Position
30 September 2025
2025
2024
Note
£
£
Fixed assets
Intangible assets
7
219,157
Tangible assets
8
118,568
96,191
---------
--------
337,725
96,191
Current assets
Stocks
3,000
3,000
Debtors
9
508,220
476,351
Cash at bank and in hand
329,047
685,077
---------
------------
840,267
1,164,428
Creditors: amounts falling due within one year
10
350,493
543,407
---------
------------
Net current assets
489,774
621,021
---------
---------
Total assets less current liabilities
827,499
717,212
Creditors: amounts falling due after more than one year
11
241,335
295,740
Provisions
( 99,283)
( 140,653)
---------
---------
Net assets
685,447
562,125
---------
---------
Capital and reserves
Called up share capital
1,424,143
1,424,143
Share premium account
254,697
254,697
Profit and loss account
( 993,393)
( 1,116,715)
------------
------------
Shareholder funds
685,447
562,125
------------
------------
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
For the year ending 30 September 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
Diagnostic World Limited
Statement of Financial Position (continued)
30 September 2025
These financial statements were approved by the board of directors and authorised for issue on 27 May 2026 , and are signed on behalf of the board by:
Mr S Farnell
Director
Company registration number: 05937877
Diagnostic World Limited
Notes to the Financial Statements
Year ended 30 September 2025
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Gateway West, East Street, Leeds, LS9 8DA.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Revenue recognition
Turnover from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract.
Intangible assets
Intangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated amortisation and impairment losses. Any intangible assets carried at revalued amounts, are recorded at the fair value at the date of revaluation, as determined by reference to an active market, less any subsequent accumulated amortisation and subsequent accumulated impairment losses. Intangible assets acquired as part of a business combination are only recognised separately from goodwill when they arise from contractual or other legal rights, are separable, the expected future economic benefits are probable and the cost or value can be measured reliably.
Amortisation
Amortisation of software intellectual property is calculated on a straight line basis over an estimated useful economic life of five years. Only software modules that are fully developed, live, and actively in use are subject to amortisation. Modules or features that remain under development are not amortised until the development phase is complete and the assets are available for use. This approach ensures that the amortisation charge reflects the period over which the software is expected to generate economic benefit
Development costs
-
Calculated on a straight line basis over 5 years
If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.
Research and development
Research expenditure is written off in the period in which it is incurred. Development expenditure incurred is capitalised as an intangible asset only when all of the following criteria are met: - It is technically feasible to complete the intangible asset so that it will be available for use or sale; - There is the intention to complete the intangible asset and use or sell it; - There is the ability to use or sell the intangible asset; - The use or sale of the intangible asset will generate probable future economic benefits; - There are adequate technical, financial and other resources available to complete the development and to use or sell the intangible asset; and - The expenditure attributable to the intangible asset during its development can be measured reliably. Expenditure that does not meet the above criteria is expensed as incurred.
Tangible assets
Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
Fixtures and fittings
-
33% straight line
Equipment
-
Between 20% and 33% straight line
Scanners
-
Between 20% and 33% straight line
Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
Stocks
Stocks are not for resale but are the Company's stock of consumables held for its own use. Cost is based on the cost of the purchase on a first in, first out basis.
Provisions
Provisions are recognised when the entity has an obligation at the reporting date as a result of a past event, it is probable that the entity will be required to transfer economic benefits in settlement and the amount of the obligation can be estimated reliably. Provisions are recognised as a liability in the statement of financial position and the amount of the provision as an expense. Provisions are initially measured at the best estimate of the amount required to settle the obligation at the reporting date and subsequently reviewed at each reporting date and adjusted to reflect the current best estimate of the amount that would be required to settle the obligation. Any adjustments to the amounts previously recognised are recognised in profit or loss unless the provision was originally recognised as part of the cost of an asset. When a provision is measured at the present value of the amount expected to be required to settle the obligation, the unwinding of the discount is recognised as a finance cost in profit or loss in the period it arises.
Financial instruments
A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost.
Defined contribution plans
Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund. When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised as a finance cost in profit or loss in the period in which it arises.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 64 (2024: 67 ).
5. Profit before taxation
Profit before taxation is stated after charging:
2025
2024
£
£
Depreciation of tangible assets
79,991
47,269
6. Tax on profit/(loss)
Major components of tax expense
2025
2024
£
£
Deferred tax:
Origination and reversal of timing differences
41,370
38,876
--------
--------
Tax on profit/(loss)
41,370
38,876
--------
--------
Reconciliation of tax expense
The tax assessed on the profit/(loss) on ordinary activities for the year is higher than (2024: higher than) the standard rate of corporation tax in the UK of 25 % (2024: 25 %).
2025
2024
£
£
Profit/(loss) on ordinary activities before taxation
164,692
( 62,827)
---------
--------
Profit/(loss) on ordinary activities by rate of tax
41,173
36,793
Effect of expenses not deductible for tax purposes
1,592
3,032
Effect of capital allowances and depreciation
( 5,595)
7,737
Utilisation of tax losses
( 37,170)
( 47,562)
Deferred tax
53,096
38,876
---------
--------
Tax on profit/(loss)
53,096
38,876
---------
--------
7. Intangible assets
Development costs
£
Cost
Additions
231,237
---------
At 30 September 2025
231,237
---------
Amortisation
Charge for the year
12,080
---------
At 30 September 2025
12,080
---------
Carrying amount
At 30 September 2025
219,157
---------
At 30 September 2024
---------
8. Tangible assets
Fixtures and fittings
Equipment
Scanners
Total
£
£
£
£
Cost
At 1 October 2024
7,453
126,374
522,452
656,279
Additions
21,815
81,387
103,202
Disposals
( 7,453)
( 68,535)
( 30,001)
( 105,989)
-------
---------
---------
---------
At 30 September 2025
79,654
573,838
653,492
-------
---------
---------
---------
Depreciation
At 1 October 2024
7,453
88,895
463,740
560,088
Charge for the year
13,916
66,075
79,991
Disposals
( 7,453)
( 67,701)
( 30,001)
( 105,155)
-------
---------
---------
---------
At 30 September 2025
35,110
499,814
534,924
-------
---------
---------
---------
Carrying amount
At 30 September 2025
44,544
74,024
118,568
-------
---------
---------
---------
At 30 September 2024
37,479
58,712
96,191
-------
---------
---------
---------
9. Debtors
2025
2024
£
£
Trade debtors
295,517
274,260
Other debtors
212,703
202,091
---------
---------
508,220
476,351
---------
---------
10. Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
153,255
304,678
Social security and other taxes
46,729
22,909
Pensions payable
6,054
4,710
Other creditors
1,024
118,971
Other creditors
143,431
92,139
---------
---------
350,493
543,407
---------
---------
11. Creditors: amounts falling due after more than one year
2025
2024
£
£
Other loans
241,335
295,740
---------
---------
Loan accrues interest at 3% p.a. and repayment is based on performance criteria.
12. Deferred tax
The deferred tax included in the statement of financial position is as follows:
2025
2024
£
£
Included in provisions
( 99,283)
( 140,653)
--------
---------
The deferred tax account consists of the tax effect of timing differences in respect of:
2025
2024
£
£
Accelerated capital allowances
( 17,424)
( 33,350)
Unused tax losses
( 71,310)
( 107,303)
--------
---------
(88,734)
(140,653)
--------
---------
13. True up adjustment
As part of the Share Purchase Agreement (SPA) between the Company's former parent and J Leonard, the Company was required to make a balancing payment of £413,971 to the seller.
This adjustment reflected a post-completion reconciliation of pre-completion trading balances, and was settled directly by the Company in accordance with the SPA.
The amount is considered to relate to pre-acquisition activity and therefore has been recognised as a charge to the Pre-Acquisition Reserve. It has not been presented within the profit and loss account in accordance with the requirements of FRS 102.
14. Contingencies
There are no known contingent liabilities as at the balance sheet date.
15. Controlling party
Diagnostic World Limited was sold out of the Inhealth Group Limited in May 2024 and so no longer has a parent undertaking. In 2023 the company considered InHealth Group Limited, incorporated in England and Wales, to be its ultimate parent undertaking with effect from 30th June 2022. It's immediate parent was C7 Health Limited.